EP4713680A2 - Y-chromosomengensignatur als target für krebstherapie in kombination mit immuntherapie - Google Patents

Y-chromosomengensignatur als target für krebstherapie in kombination mit immuntherapie

Info

Publication number
EP4713680A2
EP4713680A2 EP24807892.5A EP24807892A EP4713680A2 EP 4713680 A2 EP4713680 A2 EP 4713680A2 EP 24807892 A EP24807892 A EP 24807892A EP 4713680 A2 EP4713680 A2 EP 4713680A2
Authority
EP
European Patent Office
Prior art keywords
inhibitor
genes
chromosome
uty
kdm5d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24807892.5A
Other languages
English (en)
French (fr)
Inventor
Dan Theodorescu
Hany ABDEL-HAFIZ
Johanna M. SCHAFER
Zihai Li
Jonathan Kaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Ohio State Innovation Foundation
Original Assignee
Cedars Sinai Medical Center
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Ohio State Innovation Foundation filed Critical Cedars Sinai Medical Center
Publication of EP4713680A2 publication Critical patent/EP4713680A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24807892.5A 2023-05-15 2024-05-13 Y-chromosomengensignatur als target für krebstherapie in kombination mit immuntherapie Pending EP4713680A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363466556P 2023-05-15 2023-05-15
US202463570132P 2024-03-26 2024-03-26
PCT/US2024/029111 WO2024238476A2 (en) 2023-05-15 2024-05-13 Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy

Publications (1)

Publication Number Publication Date
EP4713680A2 true EP4713680A2 (de) 2026-03-25

Family

ID=93520211

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24807892.5A Pending EP4713680A2 (de) 2023-05-15 2024-05-13 Y-chromosomengensignatur als target für krebstherapie in kombination mit immuntherapie

Country Status (2)

Country Link
EP (1) EP4713680A2 (de)
WO (1) WO2024238476A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103886A (en) * 1997-04-11 2000-08-15 Whitehead Institute For Biomedical Research Genes in the non-recombining region of the Y chromosome
WO2015052190A1 (en) * 2013-10-07 2015-04-16 Cray Innovation Ab Predicting increased risk for cancer
KR20190092478A (ko) * 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존

Also Published As

Publication number Publication date
WO2024238476A2 (en) 2024-11-21
WO2024238476A3 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
Abdel-Hafiz et al. Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Virassamy et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
Samstein et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Freed-Pastor et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
Guo et al. B7-H3 as a therapeutic target in advanced prostate cancer
Izar et al. A single-cell landscape of high-grade serous ovarian cancer
Unno et al. Activated ALK cooperates with N-Myc via Wnt/β-catenin signaling to induce neuroendocrine prostate cancer
Zhong et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers
EP2986736B1 (de) Genfusionen und genvarianten im zusammenhang mit krebs
Luo et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells
Ren et al. Transcription factor p73 regulates Th1 differentiation
Patel et al. A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells
WO2023109875A1 (en) Biomarkers for colorectal cancer treatment
Wu et al. MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation
Rahrmann et al. Sleeping beauty screen identifies RREB1 and other genetic drivers in human B-cell lymphoma
Chiche et al. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors
WO2023178290A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
Watson et al. VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis
Tripathi et al. Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma
WO2015143441A1 (en) Compositions, methods and kits for characterizing and screening for small cell ovarian carcinoma
US20240398831A1 (en) Compositions comprising small molecule regulators of tumor immunity and methods of using same
Morin et al. A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas
JP2023524048A (ja) 癌の免疫療法のための複合バイオマーカー
WO2023125787A1 (en) Biomarkers for colorectal cancer treatment
WO2023109876A1 (en) Biomarkers for colorectal cancer treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR